Psyrri Amanda, Yu Ziwei, Weinberger Paul M, Sasaki Clarence, Haffty Bruce, Camp Robert, Rimm David, Burtness Barbara Ann
Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA.
Clin Cancer Res. 2005 Aug 15;11(16):5856-62. doi: 10.1158/1078-0432.CCR-05-0420.
Several lines of evidence support the epidermal growth factor receptor (EGFR) as a molecular target for therapy in head and neck squamous cell carcinomas (HNSCC). Determination of tumor EGFR levels by conventional immunohistochemistry has not always predicted antitumor efficacy. Quantitative assays may provide more accurate assessment of the level of EGFR receptor in the tumor, which may thus provide more reliable prognostic and predictive information. We studied the prognostic value of quantitative assessment of EGFR in oropharyngeal squamous cell cancers treated with radiotherapy.
We studied EGFR protein expression on a tissue microarray composed of 95 oropharyngeal cancer cases using an in situ molecular-based method of quantitative assessment of protein expression (AQUA) and correlated those with clinical and pathologic data. Automated, quantitative analysis uses cytokeratin to define pixels as cancer (tumor mask) within the array spot and measures intensity of EGFR expression using a Cy5-conjugated antibody within the mask. A continuous index score is generated, which is directly proportional to the number of molecules per unit area, and cases were defined as high expressing if they were above the median expression level.
The mean follow-up time for survivors was 44.9 months, and for the entire cohort was 34.8 months. Patients with high tumor EGFR expression levels had a local recurrence rate of 58% compared with 17% for patients with low EGFR tumor expression (P < 0.01). Similarly, patients with high nuclear EGFR expression had a local recurrence rate of 54% compared with 21% for patients with low EGFR nuclear expression (P < 0.05). Additionally, patients with high tumor and nuclear EGFR levels had inferior disease-free survival compared with low expressors (19% versus 43% and 19% versus 45%, respectively. P < 0.05 for each). In multivariate analysis adjusting for well-characterized prognostic variables, high tumor and nuclear EGFR expression levels retained their prognostic significance.
The AQUA system provides a continuous measurement of EGFR on paraffin-embedded tissue and was able to reveal the association between EGFR expression and outcome expected from the biological role of EGFR. In the future, EGFR AQUA score may be useful in predicting response to EGFR-targeted therapies.
多项证据支持表皮生长因子受体(EGFR)作为头颈部鳞状细胞癌(HNSCC)治疗的分子靶点。通过传统免疫组织化学测定肿瘤EGFR水平并不总能预测抗肿瘤疗效。定量检测可能会更准确地评估肿瘤中EGFR受体的水平,从而提供更可靠的预后和预测信息。我们研究了放射治疗的口咽鳞状细胞癌中EGFR定量评估的预后价值。
我们使用基于原位分子的蛋白质表达定量评估方法(AQUA),研究了由95例口咽癌病例组成的组织微阵列上的EGFR蛋白表达,并将其与临床和病理数据相关联。自动定量分析使用细胞角蛋白将阵列点内的像素定义为癌症(肿瘤掩码),并使用掩码内的Cy5偶联抗体测量EGFR表达强度。生成一个连续的指数评分,该评分与每单位面积的分子数量成正比,如果病例高于中位表达水平,则定义为高表达。
幸存者的平均随访时间为44.9个月,整个队列的平均随访时间为34.8个月。肿瘤EGFR表达水平高的患者局部复发率为58%,而EGFR肿瘤表达水平低的患者为17%(P<0.01)。同样,核EGFR表达高的患者局部复发率为54%,而核EGFR表达低的患者为21%(P<0.05)。此外,肿瘤和核EGFR水平高的患者与低表达者相比,无病生存率较差(分别为19%对43%和19%对45%。每组P<0.05)。在对特征明确的预后变量进行调整的多变量分析中,高肿瘤和核EGFR表达水平保留了其预后意义。
AQUA系统可对石蜡包埋组织中的EGFR进行连续测量,并能够揭示EGFR表达与EGFR生物学作用预期结果之间的关联。未来,EGFR AQUA评分可能有助于预测对EGFR靶向治疗的反应。